ULK1 and JNK are involved in mitophagy incurred by LRRK2 G2019S expression

Protein and Cell

Volumn 4, Issue 9, 2013, Pages 711-721

  Zhu, Yuangang ^a   Wang, Chunyan ^a   Yu, Mei ^a   Cui, Jie ^a   Liu, Liang ^a   Xu, Zhiheng ^a  

^a INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

Author keywords

DLP1; JNK; LRRK2; mitophagy; Parkinson's disease; ULK1

Indexed keywords

DNM1L PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; LEUCINE RICH REPEAT KINASE 2; LRRK2 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; MITOCHONDRIAL PROTEIN; MUTANT PROTEIN; RECOMBINANT PROTEIN; SERINE THREONINE PROTEIN KINASE ULK1; SIGNAL PEPTIDE; ULK1 PROTEIN, HUMAN;

AMINO ACID SUBSTITUTION; ANTAGONISTS AND INHIBITORS; AUTOPHAGOSOME; CHEMISTRY; GENE SILENCING; GENETICS; HELA CELL LINE; HUMAN; METABOLISM; MITOPHAGY; MUTATION; PARKINSON DISEASE; PATHOLOGY; PHYSIOLOGY; PROTEIN DOMAIN; SIGNAL TRANSDUCTION;

AMINO ACID SUBSTITUTION; AUTOPHAGOSOMES; AUTOPHAGY-RELATED PROTEIN-1 HOMOLOG; GENE KNOCKDOWN TECHNIQUES; GTP PHOSPHOHYDROLASES; HELA CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUCINE-RICH REPEAT SERINE-THREONINE PROTEIN KINASE-2; MAP KINASE SIGNALING SYSTEM; MICROTUBULE-ASSOCIATED PROTEINS; MITOCHONDRIAL DEGRADATION; MITOCHONDRIAL PROTEINS; MUTANT PROTEINS; MUTATION; PARKINSON DISEASE; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECOMBINANT PROTEINS;

EID: 84892875987     PISSN: 1674800X     EISSN: 16748018     Source Type: Journal    
DOI: 10.1007/s13238-013-3910-3     Document Type: Article

References (49)

1. Alegre-Abarrategui, J., and Wade-Martins, R. (2009). Parkinson disease, LRRK2 and the endocytic-autophagic pathway. Autophagy 5, 1208-1210.
2. Becker, E. B., and Bonni, A. (2006). Pin1 mediates neural-specific activation of the mitochondrial apoptotic machinery. Neuron 49, 655-662.
3. Berwick, D. C., and Harvey, K. (2011). LRRK2 signaling pathways: the key to unlocking neurodegeneration? Trends Cell Biol 21, 257-265.
4. Borsello, T., Clarke, P. G., Hirt, L., Vercelli, A., Repici, M., Schorderet, D. F., Bogousslavsky, J., and Bonny, C. (2003). A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med 9, 1180-1186.
5. Bravo-San Pedro, J. M., Niso-Santano, M., Gomez-Sanchez, R., Pizarro-Estrella, E., Aiastui-Pujana, A., Gorostidi, A., Climent, V., Lopez de Maturana, R., Sanchez-Pernaute, R., Lopez de Munain, A., et al. (2013). The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway. Cell Mol Life Sci 70, 121-136.
6. Chen, C. Y., Weng, Y. H., Chien, K. Y., Lin, K. J., Yeh, T. H., Cheng, Y. P., Lu, C. S., and Wang, H. L. (2012). (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. Cell Death Differ 19, 1623-1633.
7. Chen, H., and Chan, D. C. (2009). Mi tochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases. Hum Mol Genet 18, R169-176.
8. Cookson, M. R. (2010). The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 11, 791-797.
9. Cui, J., Yu, M., Niu, J., Yue, Z., and Xu, Z. (2011). Exp ression of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibits the Processing of uMtCK to Induce Cell Death in cell culture model system. Biosci Rep. (In Press).
10. Cui, J., Zhang, M., Zhang, Y. Q., and Xu, Z. H. (2007). JNK pathway: diseases and therapeutic potential. Acta Pharmacol Sin 28, 601-608.
11. Dagda, R. K., Zhu, J., and Chu, C. T. (2009). Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models. Mitochondrion 9, 289-298.
12. Egan, D. F., Shackelford, D. B., Mihaylova, M. M., Gelino, S., Kohnz, R. A., Mair, W., Vasquez, D. S., Joshi, A., Gwinn, D. M., Taylor, R., et al. (2011). Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331, 456-461.
13. Exner, N., Lutz, A. K., Haass, C., and Winklhofer, K. F. (2012). Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J 31, 3038-3062.
14. Friedman, L. G., Lachenmayer, M. L., Wang, J., He, L., Poulose, S. M., Komatsu, M., Holstein, G. R., and Yue, Z. (2012). Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of alpha-synuclein and LRRK2 in the brain. J Neurosci 32, 7585-7593.
15. Gloeckner, C. J., Schumacher, A., Boldt, K., and Ueffing, M. (2009). The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem 109, 959-968.
16. Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M. P., Beilina, A., Blackinton, J., Thomas, K. J., et al. (2006). Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23, 329-341.
17. Harris, H., and Rubinsztein, D. C. (2012). Control of autophagy as a therapy for neurodegenerative disease. Nat Rev Neurol 8, 108-117.
18. He, Y., Kamenecka, T. M., Shin, Y., Song, X., Jiang, R., Noel, R., Duckett, D., Chen, W., Ling, Y. Y., Cameron, M. D., et al. (2011). Sy nthesis and SAR of novel quinazolines as potent and brain-penetrant cjun N-terminal kinase (JNK) inhibitors. Bioorg Med Chem Lett 21, 1719-1723.
19. Hsu, C. H., Chan, D., and Wolozin, B. (2010). LRRK2 and the stress response: interaction with MKKs and JNK-interacting proteins. Neurodegener Dis 7, 68-75.
20. Itakura, E., Kishi-Itakura, C., Koyama-Honda, I., and Mizushima, N. (2012). Structures containing Atg9A and the ULK1 complex independently target depolarized mitochondria at initial stages of Parkin-mediated mitophagy. J Cell Sci 125, 1488-1499.
21. Itoh, K., Nakamura, K., Iijima, M., and Sesaki, H. (2013). Mitochondrial dynamics in neurodegeneration. Trends Cell Biol 23, 64-71.
22. Jankowski, M. (2007). [The role of JNK pathway in familial Parkinson's disease]. Postepy Biochem 53, 297-303.
23. Kuan, C. Y., and Burke, R. E. (2005). Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy. Curr Drug Targets CNS Neurol Disord 4, 63-67.
24. Kukekov, N. V., Xu, Z., and Greene, L. A. (2006). Direct interaction of the molecular scaffolds POSH and JIP is required for apoptotic activation of JNKs. J Biol Chem 281, 15517-15524.
25. Kumari, U., and Tan, E. K. (2009). LRRK2 in Parkinson's disease: genetic and clinical studies from patients. FEBS J 276, 6455-6463.
26. Kundu, M., Lindsten, T., Yang, C. Y., Wu, J., Zhao, F., Zhang, J., Selak, M. A., Ney, P. A., and Thompson, C. B. (2008). Ulk1 plays a critical role in the autophagic clearance of mitochondria and ribosomes during reticulocyte maturation. Blood 112, 1493-1502.
27. Levine, B., and Kroemer, G. (2008). Autophagy in the pathogenesis of disease. Cell 132, 27-42.
28. Li, X., Patel, J. C., Wang, J., Avshalumov, M. V., Nicholson, C., Buxbaum, J. D., Elder, G. A., Rice, M. E., and Yue, Z. (2010). Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci 30, 1788-1797.
29. Li, X., Tan, Y. C., Poulose, S., Olanow, C. W., Huang, X. Y., and Yue, Z. (2007). Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem 103, 238-247.
30. Manzoni, C. (2012). LRRK2 and autophagy: a common pathway for disease. Biochem Soc Trans 40, 1147-1151.
31. Mizushima, N. (2010). The role of the Atg1/ULK1 complex in autophagy regulation. Curr Opin Cell Biol 22, 132-139.
32. Niu, J., Yu, M., Wang, C., and Xu, Z. (2012). Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein. J Neurochem 122, 650-658.
33. Orenstein, S. J., Kuo, S. H., Tasset, I., Arias, E., Koga, H., Fernandez-Carasa, I., Cortes, E., Honig, L. S., Dauer, W., Consiglio, A., et al. (2013). Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci 16, 394-406.
34. Ramonet, D., Daher, J. P., Lin, B. M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., Yang, L., et al. (2011). Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 6, e18568.
35. Rodriguez-Enriquez, S., Kai, Y., Maldonado, E., Currin, R. T., and Lemasters, J. J. (2009). Roles of mitophagy and the mitochondrial permeability transition in remodeling of cultured rat hepatocytes. Autophagy 5, 1099-1106.
36. Saha, S., Guillily, M. D., Ferree, A., Lanceta, J., Chan, D., Ghosh, J., Hsu, C. H., Segal, L., Raghavan, K., Matsumoto, K., et al. (2009). LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci 29, 9210-9218.
37. Santos, D., and Cardoso, S. M. (2012). Mitochondrial dynamics and neuronal fate in Parkinson's disease. Mitochondrion 12, 428-437.
38. Springer, W., and Kahle, P. J. (2011). Regulation of PINK1-Parkinmediated mitophagy. Autophagy 7, 266-278.
39. Stephan, J. S., and Herman, P. K. (2006). The regulation of autophagy in eukaryotic cells: do all roads pass through Atg1? Autophagy 2, 146-148.
40. Tamura, Y., Itoh, K., and Sesaki, H. (2011). Sn apShot: Mitochondrial dynamics. Cell 145, 1158, 1158. e1.
41. Tong, Y., and Shen, J. (2012). Genetic analysis of Parkinson's diseaselinked leucine-rich repeat kinase 2. Biochem Soc Trans 40, 1042-1046.
42. Tournier, C., Hess, P., Yang, D. D., Xu, J., Turner, T. K., Nimnual, A., Bar-Sagi, D., Jones, S. N., Flavell, R. A., and Davis, R. J. (2000). Requirement of JNK for stress-induced activation of the cytochrome cmediated death pathway. Science 288, 870-874.
43. Wang, X., Yan, M. H., Fujioka, H., Liu, J., Wilson-Delfosse, A., Chen, S. G., Perry, G., Casadesus, G., and Zhu, X. (2012). LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet 21, 1931-1944.
44. West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., and Dawson, T. M. (2005). Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102, 16842-16847.
45. West, A. B., Moore, D. J., Choi, C., Andrabi, S. A., Li, X., Dikeman, D., Biskup, S., Zhang, Z., Lim, K. L., Dawson, V. L., et al. (2007). Parkinson's disease-associated mutations in LRRK2 link enhanced GTPbinding and kinase activities to neuronal toxicity. Hum Mol Genet 16, 223-232.
46. White, L. R., Toft, M., Kvam, S. N., Farrer, M. J., and Aasly, J. O. (2007). MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease. J Neurosci Res 85, 1288-1294.
47. Xu, Z., Kukekov, N. V., and Greene, L. A. (2003). POSH acts as a scaffold for a multiprotein complex that mediates JNK activation in apoptosis. EMBO J 22, 252-261.
48. Xu, Z., Kukekov, N. V., and Greene, L. A. (2005). Regulation of apoptotic c-Jun N-terminal kinase signaling by a stabilization-based feedforward loop. Mol Cell Biol 25, 9949-9959.
49. Xu, Z., Maroney, A. C., Dobrzanski, P., Kukekov, N. V., and Greene, L. A. (2001). The MLK family mediates c-Jun N-terminal kinase activation in neuronal apoptosis. Mol Cell Biol 21, 4713-4724.